Mighty Therapeutics Secures $150 Million Investment for Growth and Development

Mighty Therapeutics Holdings Inc. has recently closed transactions securing up to $150 million in non-dilutive growth and equity capital. The company has partnered with K2 HealthVentures to receive a credit facility of up to $125 million, including an initial $30 million tranche. Additionally, the company has held an initial closing of its Series B financing, with Morningside investing $25 million. T

his investment is expected to support the acceleration of launch activities and late-stage development initiatives, as well as extend the company's cash runway into 2028. The subsequent drawdowns available under the K2HV facility are anticipated to secure the runway to projected cash flow positivity in early 2029. Mighty Therapeutics expressed gratitude for Morningside's ongoing support and excitement to partner with K2 HealthVentures.

The company's CEO, Reenie McCarthy, emphasized that the financings secure their access to the additional capital necessary to reach cash flow positivity, supporting their leadership in the field of mitochondrial medicine. The company's commercial momentum and promising pipeline position them for long-term growth and continued patient impact. Under the K2HV credit facility, term loans are expected to be available for drawdown through early 2029, subject to specified milestones.

Mighty Therapeutics, along with its subsidiary Stealth BioTherapeutics Inc., is dedicated to advancing novel therapies for people living with diseases involving mitochondrial dysfunction. The company's development portfolio includes rare and age-related diseases, and it continues to progress its clinical candidates for various conditions.